Nurix Therapeutics, Inc.

NasdaqGM:NRIX Stock Report

Market Cap: US$801.1m

Nurix Therapeutics Valuation

Is NRIX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NRIX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NRIX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NRIX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NRIX?

Key metric: As NRIX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NRIX. This is calculated by dividing NRIX's market cap by their current revenue.
What is NRIX's PS Ratio?
PS Ratio9.8x
SalesUS$83.69m
Market CapUS$801.13m

Price to Sales Ratio vs Peers

How does NRIX's PS Ratio compare to its peers?

The above table shows the PS ratio for NRIX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average19.4x
URGN UroGen Pharma
8.7x39.52%US$839.2m
MYGN Myriad Genetics
0.9x4.50%US$749.9m
TNGX Tango Therapeutics
39.7x48.87%US$1.0b
BCYC Bicycle Therapeutics
28.3x55.33%US$574.6m
NRIX Nurix Therapeutics
9.8x26.06%US$801.1m

Price-To-Sales vs Peers: NRIX is good value based on its Price-To-Sales Ratio (9.8x) compared to the peer average (19.4x).

Price to Sales Ratio vs Industry

How does NRIX's PS Ratio compare vs other companies in the US Biotechs Industry?

156 CompaniesPrice / SalesEstimated GrowthMarket Cap
AMGN Amgen
4.6x2.23%US$162.12b
REGN Regeneron Pharmaceuticals
4.3x6.21%US$60.07b
BIIB Biogen
2.2x-1.24%US$21.44b
INCY Incyte
3.8x1.84%US$17.20b
NRIX 9.8xIndustry Avg. 11.3xNo. of Companies156PS020406080100+
156 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NRIX is good value based on its Price-To-Sales Ratio (9.8x) compared to the US Biotechs industry average (11.3x).

Price to Sales Ratio vs Fair Ratio

What is NRIX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NRIX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.8x
Fair PS Ratio0.08x

Price-To-Sales vs Fair Ratio: NRIX is expensive based on its Price-To-Sales Ratio (9.8x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NRIX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$10.63
US$28.74
+170.34%
24.03%US$41.00US$12.00n/a19
Oct ’26US$9.40
US$29.83
+217.38%
21.59%US$41.00US$16.00n/a18
Sep ’26US$9.34
US$29.83
+219.41%
21.59%US$41.00US$16.00n/a18
Aug ’26US$11.04
US$29.83
+170.23%
21.59%US$41.00US$16.00n/a18
Jul ’26US$11.71
US$30.33
+159.04%
20.94%US$41.00US$16.00n/a18
Jun ’26US$10.63
US$30.28
+184.83%
21.06%US$41.00US$16.00n/a18
May ’26US$11.16
US$30.00
+168.82%
21.51%US$41.00US$16.00n/a17
Apr ’26US$10.47
US$31.22
+198.21%
20.36%US$41.00US$16.00n/a18
Mar ’26US$15.45
US$32.28
+108.92%
16.16%US$41.00US$17.00n/a18
Feb ’26US$19.71
US$32.22
+63.48%
16.70%US$41.00US$16.00n/a18
Jan ’26US$18.84
US$32.11
+70.44%
16.48%US$41.00US$16.00n/a18
Dec ’25US$22.11
US$31.44
+42.19%
17.35%US$41.00US$16.00n/a16
Nov ’25US$24.47
US$31.20
+27.50%
17.80%US$41.00US$16.00n/a15
Oct ’25US$22.09
US$29.38
+33.02%
17.53%US$36.00US$15.00US$9.4013
Sep ’25US$25.20
US$29.15
+15.69%
17.79%US$36.00US$15.00US$9.3413
Aug ’25US$21.47
US$29.00
+35.07%
18.20%US$36.00US$15.00US$11.0413
Jul ’25US$20.91
US$26.50
+26.73%
20.00%US$35.00US$14.00US$11.7112
Jun ’25US$15.75
US$24.67
+56.61%
22.77%US$35.00US$14.00US$10.6312
May ’25US$13.08
US$25.09
+91.83%
22.64%US$35.00US$14.00US$11.1611
Apr ’25US$14.58
US$23.91
+63.99%
27.42%US$35.00US$10.00US$10.4711
Mar ’25US$13.56
US$23.91
+76.32%
27.42%US$35.00US$10.00US$15.4511
Feb ’25US$8.15
US$26.58
+226.18%
27.45%US$36.00US$9.00US$19.7112
Jan ’25US$10.32
US$26.58
+157.59%
27.45%US$36.00US$9.00US$18.8412
Dec ’24US$6.91
US$26.85
+288.51%
26.33%US$36.00US$9.00US$22.1113
Nov ’24US$5.66
US$27.46
+385.19%
23.54%US$36.00US$12.00US$24.4713
Oct ’24US$7.86
US$28.08
+257.21%
22.80%US$36.00US$12.00US$22.0913
US$28.74
Fair Value
63.0% undervalued intrinsic discount
19
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/22 22:58
End of Day Share Price 2025/10/22 00:00
Earnings2025/08/31
Annual Earnings2024/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nurix Therapeutics, Inc. is covered by 24 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Joel BeattyBaird
Peter LawsonBarclays